Viking Therapeutics plans to advance oral obesity drug to late-stage trial
11/02/2026 22:08
Feb 11 (Reuters) - Viking Therapeutics VKTX.O said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year. (Reporting by Sneha S K; Editing by Sriraj Kalluvila) ((Sneha.SK@thomsonreuters.com;))
Recent news on Viking Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry